HIV‐associated dysbiosis and immune recovery during antiretroviral therapy
Clinical and Translational Discovery · 2022-06 · 2 (2)
DOI: 10.1002/ctd2.58 ↗Kurz gefasst
Kommentar in der Zeitschrift Clinical and Translational Discovery, online erschienen am 28.04.2022. Verfasst von Samuel D Johnson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, United States. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
The microbiomes of people living with HIV (PLWH) are significantly dysregulated with a loss of bacteria diversity and shifts in composition, including increases in pathogenic and decreases in beneficial species. Because of the microbiome's role in modulating health, the effect of this dysbiosis on immune response in PLWH has been a significant concern, mainly because these shifts can persist even after viral suppression during combination antiretroviral therapy (cART). However, due to limitations on sample availability, few studies have been able to provide insights into these microbiome‐immune interactions. Recently, Olivas‐Martínez et al. characterized ileum and caecum mucosa‐associated microbiomes of PLWH based on their level of peripheral CD4+ T‐cell reconstitution following long‐term cART. Their analysis revealed distinct microbiome signatures predictive of recovery. Additionally, differences in markers of gut inflammation and damage between response groups were described, further implicating mucosal disruptions with immune reconstitution. These new data demonstrate an interdependence of microbiome and therapy response, and additional studies are urgently required to fully elucidate this crosstalk and microbiome dynamics from before/after infection and finally, long‐term viral suppression with cART.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, United States.
- Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, United States.
Förderung
- NIAID NIH HHS
- NINDS NIH HHS
Zitieren
APA
Johnson, S. D., & Byrareddy, S. N. (2022). HIV‐associated dysbiosis and immune recovery during antiretroviral therapy. Clinical and Translational Discovery, 2(2). https://doi.org/10.1002/ctd2.58
Vancouver
Johnson SD, Byrareddy SN. HIV‐associated dysbiosis and immune recovery during antiretroviral therapy. Clinical and Translational Discovery. 2022;2(2). doi:10.1002/ctd2.58
BibTeX
@article{Johnson2022,
author = {Johnson, Samuel D and Byrareddy, Siddappa N},
title = {HIV‐associated dysbiosis and immune recovery during antiretroviral therapy},
journal = {Clinical and Translational Discovery},
year = {2022},
volume = {2},
number = {2},
doi = {10.1002/ctd2.58}
}
EUVIMED